

Development of cell-free transcription-translation systems in three soil Pseudomonads

Joseph T. Meyerowitz^{*‡}, Elin M. Larsson^{*}, Richard M. Murray

Division of Biology and Biological Engineering, California Institute of Technology

^{*} indicates equal contributions from both authors,

[‡] indicates corresponding author, email address jmeyerow@caltech.edu

June 9, 2023

Abstract

In vitro transcription-translation (TX-TL) can enable faster engineering of biological systems. This speed-up can be significant, especially in difficult-to-transform chassis. This work shows the successful development of TX-TL systems using three soil-derived wild-type Pseudomonads known to promote plant growth: *Pseudomonas synxantha*, *Pseudomonas chlororaphis*, and *Pseudomonas aureofaciens*. One, *P. synxantha*, was further characterized. A lysate test of *P. synxantha* showed a maximum protein yield of 2.5 μM at 125 proteins per DNA template and a maximum protein synthesis rate of 20 nM/min. A set of different constitutive promoters driving mNeonGreen expression were tested in TX-TL and integrated into the genome, showing similar normalized strengths for *in vivo* and *in vitro* fluorescence. This correspondence between the TX-TL derived promoter strength and the *in vivo* promoter strength indicates these lysate-based cell-free systems can be used to characterize and engineer biological parts without genome integration, enabling a faster design-build-test cycle.

Keywords: Cell-free, synthetic biology, non-model organisms, TX-TL

25 Introduction

26 The field of synthetic biology has advanced considerably over the past years. From
27 scar-free DNA assembly [1] to CRISPR-mediated genome editing [2], new technolo-
28 gies have made it possible to tackle increasingly complex tasks in the engineering
29 and control of biological systems. Synthetic biology has advanced to a point where
30 we can reliably engineer bacteria to perform varying and complex tasks including
31 synthesis of precious chemicals [3, 4], performance of logical operations [5, 6] and
32 sensing [7].

33 Substantial challenges still remain with the use of synthetic biology tools. While the
34 cost of DNA sequencing and DNA synthesis continues to decline [8, 9], and databases
35 of genetic information [10], protein structure [11], and characterized genetic parts
36 [12, 13, 14] continue to expand, composing these separate advances into engineered
37 biological systems is complicated and incompletely systematized. Because of this
38 difficulty, new techniques in the field are often implemented only in well-understood
39 model organisms like *E. coli*, *B. subtilis*, *P. putida* and *S. cerevisiae*. To expand
40 the range of projects possible with synthetic biology, developing tools for use with
41 non-model organisms is essential. Environmental bacteria often have desirable traits
42 unavailable in model organisms, such as the ability to perform specific types of
43 metabolism [15], tolerate certain stresses and inhibitors [16] and colonize different
44 environments [17, 18, 19]. Making non-model organisms tractable for engineering
45 also enables targeted experiments to reveal the roles these organisms play in their
46 natural niches.

47 While some advances have been made in engineering non-model organisms [20, 21,
48 22], “domesticating” a non-model organism remains challenging. For a new organ-
49 ism of interest, the first steps for engineering are to find methods for cultivation and
50 transformation. A later step is to characterize genetic parts from which new circuits
51 can be built. One reason why working with non-model organisms is challenging comes
52 from the variation in each species’ underlying biology, requiring species-by-species
53 tailoring of every protocol. An example of this variation can be seen in the mecha-
54 nism for ribosomal initiation, which can have dramatic differences from commonly
55 used organisms such as *E. coli* which use Shine-Delgarno led initiation and other
56 bacteria such as *Deinococcus deserti* or *Mycobacterium tuberculosis* which frequently
57 use leaderless mRNA sequences without a Shine-Delgarno sequence [23].

58 One approach used to accelerate engineering of non-model organisms is *in vitro*
59 transcription-translation extract (TX-TL), or “cell-free”. TX-TL reactions re-comprise
60 the machinery necessary for RNA transcription and protein translation. By remov-

61 ing soluble internal components from a species of interest and producing a clarified
62 lysate, this process results in a non-living, simplified system that can be used to
63 prototype genetic parts and enzymes. TX-TL is particularly useful for the study of
64 non-model organisms that may be difficult to genetically transform or grow under
65 certain conditions. Instead of cloning and re-isolating the correct transformed cells,
66 plasmid DNA or PCR products containing the circuit can be added to a mixture of
67 the lysate and other components needed such as nucleotides and salts. This proce-
68 dure allows characterization of the test parts within hours. Genetic manipulation of
69 some non-model organisms can take days or weeks to complete.

70 Creating TX-TL reactions using extracts from non-model organisms can be challeng-
71 ing, as the activity depends on factors such as growth phase during harvest. Some
72 species have long doubling times which makes the process of reaching high cell den-
73 sities time consuming and contamination-prone. Because of the extensive knowledge
74 about the *E. coli* genome, certain genetic alterations have been shown to increase
75 *in vitro* activity by removing DNA and amino acid degrading enzymes [24]. Such a
76 strategy cannot be applied generally with non-model organisms, as the identify of
77 similar genes may not be known. Despite these challenges, TX-TL has been success-
78 fully created from non-model organisms including *B. megaterium* [25] and several
79 Streptomycetes [26].

80 In this study, we demonstrate the production and characterization of TX-TL from
81 three soil-derived wild-type Pseudomonads. This class of organisms is important
82 because of their ecological ubiquity. These species are known for promoting plant
83 growth by releasing phenazines, an antimicrobial class of molecules, into the environ-
84 ment [27, 28]. These phenazines help protect food crops from disease. It has also been
85 suggested that these molecules may play a role in nutrient cycling in the soil [29].
86 Pseudomonads also demonstrate an innate tolerance to certain growth inhibitory
87 compounds in the environment and in industrial fermentation settings. Their abil-
88 ity to tolerate solvents and certain growth inhibitors found in low-cost industrial
89 feedstock make them good candidates for commercial applications [30]. These bac-
90 teria can sometimes metabolize lignocellulosic growth inhibitors as well, showcasing
91 their evolutionary adaptation to environments abundant in plant material [31, 32].
92 Root-living bacteria typically also evolve tolerance to antimicrobial compounds, such
93 as penicillins, produced by other bacteria competing to inhabit the same ecological
94 niche [33]. The creation of these three extracts from wild-type strains expand the
95 toolkit for engineering these and other environmental bacteria.

96 Results and Discussion

97 Soil provides a high-lignin environment where soil bacteria may have evolved toler-
98 ance to certain stresses ill-tolerated by *E. coli* [34]. To find potential new chassis
99 for engineering with the desired stress tolerances, three soil-derived bacteria, *Pseu-*
100 *domonas synxantha* 2-79 (“PSX”), *Pseudomonas chlororaphis* PCL1391 (“PCL”),
101 and *Pseudomonas aureofaciens* 30-84 (“PAU”), were chosen for testing.


102 These *Pseudomonas* species have been studied separately and together as sym-
103 bionts of plant roots, where they produce anti-fungal phenazines [35, 36, 37]. The
104 phenazines from these bacteria are known to control take-all, a disease in wheat plant
105 roots, and damping-off disease, a multi-pathogen constellation of seed and seedling
106 injuries across different plant species [38].

107 *P. aureofaciens* 30-84 is also called *P. chlororaphis* subvar. *aureofaciens* 30-84, and
108 is closely related to *P. chlororaphis* PCL1391. PSX is more distantly related, with
109 a similar distance between its genome, *E. coli*, PCL, and PAU as measured by digi-
110 tal DNA-DNA hybridization [39]. The phylogenetic relationships between the three
111 target bacteria and other bacteria used for TX-TL are described in Supplementary
112 Information A. All three of the Pseudomonads are wild-type isolates without many
113 of the common mutations such as restriction system knockouts seen in more domes-
114 ticated strains [40].


115 Pseudomonads show phenotypic differences from the *E. coli* 116 BL21 Rosetta2 used in traditional TX-TL

117 To confirm the expected tolerance of some environmentally and industrially relevant
118 compounds, a series of *in vivo* growth experiments were done to compare the growth
119 ability of the Pseudomonads and a reference *E. coli* BL21 Rosetta2 strain often used
120 in *E. coli* TX-TL. First, the three Pseudomonads were grown in the presence of the
121 lignocellulosic monomer syringaldehyde. PSX showed tolerance at all tested concen-
122 trations, whereas PCL and PAU had minimal difference in their tolerance compared
123 to *E. coli* (Figure 1A). Next, we compared the tolerance of three common antibi-
124 otics (two ribosomal inhibitors and one cell-wall synthesis inhibitor) for PSX and
125 *E. coli* (Figure 1B-D). As expected PSX, which has evolved to tolerate compounds
126 frequently present in the rhizosphere, show higher tolerance than *E. coli*.


127 These results confirm that at least one of the tested Pseudomonads has meaningful
128 phenotypic differences from the standard *E. coli* for engineering purposes. The ability
129 of PSX to broadly tolerate different types of stress is promising for later uses in




(a) syringaldehyde



(b) kanamycin



(c) streptomycin



(d) carbenicillin

Figure 1: Differences in growth when exposed to (A) syringaldehyde, (B) kanamycin, (C) streptomycin and (D) carbenicillin. Barplots are showing one biological replicate of the final optical density (OD) after 24 hours of growth normalized to the OD of cells grown without any growth inhibitor.

130 bioproduction or as a biocontrol agent for agriculture.

131 ***In vitro* transcription-translation systems are possible with** 132 **three new wild-type Pseudomonads**

133 After the tolerance experiments, we continued towards the effort of making cell-free
134 extracts from the Pseudomonads with the aim of achieving functional extracts that
135 can be compared to *E. coli* extract in terms of productivity.

136 We started scale-up by growing 50 mL cultures in 250 mL baffled flasks of each
137 species with inoculum sizes of 1:100 and 1:1000 from overnight 5 mL cultures in
138 2xYTPG. Growth was sufficient to support production of cell pellets for TX-TL use,
139 shown in Supplementary Information B, and identified likely time and OD600 ranges
140 for early exponential phase harvest.

141 Scale-up continued to 660 mL scale in 2.8L baffled flasks. Cultures were harvested
142 at OD 3.0 for all three *Pseudomonas* species to begin with; initial testing showed
143 *P. chlororaphis* lysate required an earlier harvest, chosen to be at OD 1.5 (data not
144 shown). Each replicate for each species was grown on a different day in 3x 660 mL
145 volume, harvested, washed, and frozen in two 50 mL tubes.

146 Lysates were produced using one of the two frozen pellets with varying process con-
147 ditions. In previous work, two of the most important parameters to optimize after
148 harvest time have been lysis and runoff [41]. Here we try three different sonication
149 amplitudes and three different runoff times, and test each combination across six
150 different reaction conditions (Figure 2A). These varied protocol parameters show
151 different protein yields across lysates from all three species (Figure 2B).

152 One important note is that these reaction conditions were prepared by creating a
153 single mix of energy solution, amino acid mix, and PEG, then adding it to 384
154 well plates with the different salts. The pattern of increased and decreased yield is
155 unlikely to be the result of differences in the preparation of the reaction buffer, as
156 all of the data here come from the preparation of a single mixture of the common
157 reaction components.

158 **Repeating lysis production at larger scale improved yield and consistency** 159 **of *P. synxantha* TX-TL**

160 Next, three new "big batches" of PSX lysate were produced on separate days at
161 a single sonication amplitude ('50') and a single runoff time (60 minutes). These




Figure 2: All three species show productive TX-TL systems across a range of lysate preparation and reaction parameters. (a) Mean protein yield across biological replicates, different sonication amplitudes, runoff times, salt concentrations, and species, shown after 6 hours of TX-TL reaction time. (b) Individual time traces from each species showing biological replicates.




Figure 3: Salt panel for the big batches of PSX extract. (a) Variations in reaction salt optima across three batches of *P. synxantha* lysate shown after 6 hours of TX-TL reaction time. (b) Individual time traces from each batch, each chart showing technical replicates.

162 conditions were chosen based on results from the first set of replicates from the
163 sonication and runoff testing, and were not at the overall maximum yield shown
164 across the biological triplicates above. These "big batches" used the second of the
165 two frozen pellets from the triplicate growths described above. Batch 1 was made
166 from the same harvested culture as the first PSX replicate in Figure 2, Batch 2 and
167 Batch 3 correspond to the second and third cultures used as well.

168 These "big batches" show an approximately doubled protein yield and increased con-
169 sistency between biological replicates compared to the reactions in Figure 2 and were
170 produced from the same cultures. There were improvements in speed of processing
171 time due to the simpler process conditions and increased experience with processing
172 the pellets into lysates. The causes of the improvements in these follow-on lysates
173 were not explored in greater depth.

174 Potassium and magnesium salts were tested with more detail across a narrower range
175 of concentrations (Figure 3A). The test conditions show a clear fluorescent signal ac-
176 cumulating over the first 4-5 hours of the reaction for all three of the new batches
177 (Figure 3B). The yields and optimum salt concentrations vary across the different
178 batches to a degree similar to past *E. coli* TX-TL reactions. These results demon-
179 strate the extract making process was repeatable, and that there are some differences
180 in performance between the batches despite being made with the same process pa-
181 rameters.

182 **Increases in DNA template produce higher protein yields**

183 Next, using these three "big batches" of extract with their respective salt optimization
184 values, we tested a varying amount of DNA template added to the reaction (Figure
185 4A-B). Each batch of extract produced a similar amount of the fluorescent reporter
186 for a given template concentration. Across the tested template concentrations, more
187 template always results in more protein. Doubling the amount of template doubles
188 the amount of fluorescent reporter made within some of the tested range.

189 The 20 nM Pa10403 condition using the third extract batch reached the highest
190 concentration of mNeongreen among all of the PSX experiments here at approxi-
191 mately 2.5 μ M with a peak synthesis rate of 20 nM/min (Figure 4C-D). Over the
192 course of the reaction this protein yield is equal to 125 proteins produced per DNA
193 template.

194 Qualitatively all of the extracts stop producing mNeonGreen at around 4 hours
195 regardless of the amount of template that is added. In some circumstances we might




Figure 4: Fluorescence measurements at different DNA template concentrations. (a and b) Endpoint protein yield across the three *P. synxantha* extract batches with varied DNA template concentration and two different templates. (c and d) Protein synthesis rates and cumulative protein yield across the same three batches with Pa10403 template at 20.0 nM. Error bands show standard deviation across technical replicates.

196 expect more heavily burdened TX-TL reactions to exhaust some key resource earlier
197 than less burdened reactions, but that is not what we see here. Protein synthesis
198 rates are similar across all three batches in the early part of the reaction through
199 the peak. The differences in protein yield between the extracts are attributable to
200 different rates of the reaction slowing post-peak.

201 Promoters tested *in vivo* and *in vitro* show similar strengths

202 To evaluate whether we could use the *P. synxantha* extract for prototyping of genetic
203 elements as seen in previous studies of *E. coli* [42] and *B. megaterium* [25], we
204 compared protein synthesis levels for 11 different constitutive promoters from *E. coli*
205 and *P. putida* driving expression of a genomically integrated fusion with the green
206 fluorescent protein mNeonGreen (Figure 5).




Figure 5: Constitutive promoters driving the expression of mNeonGreen were compared *in vivo* in *P. synxantha* living cells and *in vitro* in *P. synxantha* cell-free extract. All expression levels are normalized to the expression level of the strongest promoter fusion using the Pa10403 promoter.

207 The fluorescence below is normalized by optical density at 500 nm at 24 hours of
208 growth. To compare the results from the *in vitro* TX-TL reactions, we take the
209 fluorescence from a time course at 6 hours into the reaction. We then normalize
210 all fluorescence values to the largest fluorescence value of the strongest promoter
211 Pa10403 [43]. The reactions *in vitro*, regardless of promoter strength, all stop pro-
212 ducing protein at approximately the same time.

213 We can distinguish between strong and weak constitutive promoters using cell-free
214 prototyping, but we cannot always accurately predict the rank of strength within
215 these groups, as seen in previous work [25]. The normalized fluorescence in the
216 TX-TL reactions is consistently lower than the corresponding *in vivo* values. Even
217 though the *in vivo* to TX-TL comparison is not perfectly matched, the number of
218 genetic elements that need to be tested *in vivo* can be reduced by first prototyping
219 them using the TX-TL system. This also highlights the limitation of using TX-TL
220 as a prototyping tool for *in vivo* expression.

221 Conclusion

222 Together these experiments show that our target *Pseudomonas* spp. have pre-existing
223 tolerance to some growth inhibitors that reduce the growth capacity of *E. coli*, and
224 these species are tractable for further engineering work. The TX-TL measurements
225 of the promoter panel match the *in vivo* measurements of the same promoters. This
226 shows the TX-TL system can be used for characterizing parts for later use *in vivo*.
227 The ability to perform TX-TL reactions with these species is a key component of
228 engineering and rapid prototyping with new non-model organisms. A working TX-
229 TL system can enable a faster design-build-test cycle, and make characterization of
230 new parts practical.

231 Methods

232 Bacterial strains and growth conditions

233 *Pseudomonas synxantha* 2-79, *Pseudomonas chlororaphis* PCL1391, and *Pseudomonas*
234 *aureofaciens* 30-84 were obtained from the Newman lab at Caltech. Cells were grown
235 by streaking onto 2xYTPG (16 g/L tryptone, 10 g/L yeast extract, 5 g/L NaCl, 40
236 mM potassium phosphate dibasic, 22 mM potassium phosphate monobasic, 2% glu-
237 cose) agar or LB (10 g/L tryptone, 5 g/L yeast extract, 5 g/L NaCl) agar without
238 antibiotics and incubating for 18-36 hours at 30°C. Individual colonies were picked

239 and grown in 5 mL of 2xYTPG with shaking at 200-220 rpm at 30°C overnight. As
240 needed, 50 mL of 2xYTPG in a 250 mL baffled flask or 660 mL of 2xYTPG in a
241 2.8L baffled flask with an adhesive AirOTop sterile seal would be inoculated 1:1000
242 the next day. Cell growth was monitored by optical density at 500 nm or 600 nm,
243 with 1:1, 1:4, 1:16, 1:64, and 1:256 dilutions of culture samples prepared in fresh
244 2xYTPG media to stay in the Biotek H1MF plate reader linear range for absorption
245 measurements (OD 0.005 to 0.5).

246 ***In vivo* growth inhibition tests**

247 Cells were grown with continuous shaking in a Biotek H1MF plate reader for 24 hours.
248 The cells were grown in LB medium with added growth inhibitor in serial dilutions
249 with a starting concentration of 10 mM syringaldehyde, 50 µg/ml streptomycin, 100
250 µg/ml kanamycin and 200 µg/ml carbenicillin. *P. synxantha* was grown at 30°C and
251 *E. coli* was grown at 37°C.

252 **Construction of DNA templates**

253 DNA parts including promoters, ribosome binding sites, reporters, terminators, and
254 backbones with antibiotic resistance were amplified by PCR in NEB Q5 2x Master
255 Mix, purified by gel extraction and QIAGEN MinElute spin columns, and assembled
256 using NEB Hifi 2x Master Mix. Supplemental Information F shows the plasmid map
257 for a strong constitutive promoter expressing mNeonGreen, and the plasmid map for
258 a promoter with a different strength also expressing mNeonGreen.

259 **Measurement of protein concentration**

260 For each extract produced for the sonication, runoff, and salt panels, protein concen-
261 tration was measured using a Bradford assay. In brief, a 1:50 dilution of lysate was
262 prepared in Tris-buffered saline. A bovine serum albumin standard was used to pre-
263 pare 8 different concentrations for a standard curve. Standard curves were prepared
264 in triplicate on every 96-well plate used for protein measurement, and samples were
265 also prepared in triplicate.

266 **Production of *Pseudomonas* cell-free extracts**

267 The protocol from Sun et al [36] and the protocol from Kwon et al [37] for *E. coli* TX-
268 TL was repurposed for the *Pseudomonas* TX-TL protocol with minor modifications.

269 An illustrated and expanded version of our protocol is shown in Supplement X.
270 Briefly, cells are grown on 2xYTPG agar. After 18-36 hours of growth at 30°C, the
271 plates are stored at 4C for up to a month. Individual colonies are picked and used to
272 grow 5 mL overnight cultures in 14 mL tubes. 2.8L baffled shake flasks with 660 mL
273 of 2xYTPG are inoculated 1:1000 the next day and grown for 8-12 hours. Note that
274 unlike past protocols, the final culture is inoculated directly from a 5 mL overnight,
275 without an intermediate 50 mL culture, with a smaller inoculum.

276 The larger culture is grown to the harvest optical density (OD 1.5 +/- 10% for
277 *P. chlororaphis*, OD 3.0 +/- 10% for *P. synxantha* and *P. aureofaciens*). Optical
278 density is measured once per 60 minutes until the last doubling of the growth, then
279 monitoring increases to once per 20 minutes. Dilutions of 1:4, 1:16, 1:64, or 1:256 in
280 fresh 2xYTPG media are used to produce a sample with a 600nm absorption over
281 0.05 and under 0.5. 200 mL of Buffer A (1.8 g/L Tris-acetate, 3 g/L Mg-acetate,
282 and 12.2 g/L K-glutamate, adjusted to pH 8.2 with 2M Tris and autoclaved, then 1
283 mL / L of 1M DTT is added) is frozen in 1L centrifuge tubes stored at -20C at an
284 angle for 1-2 hours.

285 At harvest time, the cell culture is decanted into the 1L centrifuge tube over the ice.
286 This brings the culture temperature down from 30°C to 10°C within a few minutes.
287 The cell culture is centrifuged at 4800g for 12 minutes at 4°C. The supernatant is
288 decanted, and the tubes are placed on ice. The cell pellet is resuspended in Buffer
289 A, then otherwise follows the Sun et al. *E. coli* protocol with two wash steps in 1L
290 bottles, a final wash step and transfer into two weighed 50 mL tubes, flash freezing
291 in liquid nitrogen, and stored at -80°C.

292 At a later time, the cell pellet is removed from the freezer and placed on wet ice to
293 thaw. 1 mL / g of Buffer A is used to resuspend the pellet, then 4 mL of resuspended
294 cell pellet is added to each 14 mL falcon tube. Each tube is sonicated on wet ice for
295 120s, 5s on, 10s off, with an amplitude of 10, 25, or 50 on a Qsonica Q700 with a
296 1/8" stepped microtip and microtip coupler. The tubes are centrifuged at 12,000g
297 for 10 minutes at 4°C. The supernatant is transferred to new 1.4 mL or 14 mL tubes
298 and incubated in a "runoff" step with open lids shaking at 220 rpm at 30C for 0-
299 60 minutes. These tubes are centrifuged again at 12,000g for 10 minutes at 4°C,
300 then the supernatant is transferred to new tubes for freezing in LN2 and storage at
301 -80C.

302 **TX-TL reaction conditions**

303 Reaction conditions also follow the *E. coli* protocol in Sun et. al. (34). In brief,
304 each 10 microliter reaction in a 384 well plate contains 29% buffer, 13% potassium
305 and magnesium glutamate salts, 25% DNA template, and 33% processed lysate.
306 The buffer consists of 26% energy solution, 57% amino acid mix, and 17% 40%
307 PEG-8000. These are mixed on ice and hand-pipetted carefully to avoid introducing
308 bubbles. Individual reactions are prepared in glass-bottomed 384 well plates sealed
309 with an oxygen-permeable Breathe-Easy seal. The plate is centrifuged for 2 minutes
310 to mix the reagents and reduce bubbles in the wells, then read at 30°C in the plate
311 reader.

312 **Preparation of DNA template for TX-TL reactions**

313 *E. coli* JM109 or DH10B cells with DNA constructs were grown to 100 mL (midiprep)
314 or 400 mL (maxiprep) scale. Pellets were processed using Macherey-Nagel midiprep
315 or maxiprep kits to produce 100s to 1000s of micrograms of purified DNA, including
316 a “finalizer” step to re-purify and concentrate the eluate from the kit. DNA is
317 diluted to produce a concentration of 10 nM in the final reaction unless otherwise
318 specified.

319 **Measurement of *in vitro* fluorescence**

320 Biotek H1M and H1MF plate readers were used to measure fluorescence of mNeon-
321 Green (excitation 490 nm, emission 520 nm) and optical density (500 nm and 600
322 nm). mNeonGreen protein was purified using a his-tag and NiNTA columns, and
323 UV absorption was used to quantify the amount of purified protein. Triplicate dilu-
324 tions at 8 concentrations from 20 nM to 0 nM in 1xPBS were measured five times
325 in all plate readers, and separate standard curves were created for each plate reader.
326 Dilutions were incubated at 30°C during fluorescence measurements.

327 **Construction of constitutively fluorescent *P. synxantha***

328 All cloning to produce *P. synxantha* genomic integration constructs was done using
329 *E. coli* DH10B with the backbone pJM220 [44]. Constitutive promoters from *E. coli*
330 (<http://parts.igem.org/Promoters/Catalog/Anderson>) and *P. putida* [45] were fused
331 to the fluorescent protein mNeonGreen. The constructs were then integrated on the
332 *P. synxantha* chromosome using transposase based insertion at the Tn7 site. The

333 protocol used for making and transforming competent cells was modified from Choi
334 et al [46].

335 Briefly, electrocompetent *P. synxantha* cells were electroporated in 1 mm-gap cu-
336 vettes (at 1.8 mV, 600 Ω and 10 μ F) with the construct plasmid as well as a plasmid
337 containing the transposase and genes required for genome insertion [47]. The cells
338 were then recovered in rich medium (SOC) for 3 hours at 30°C and plated onto
339 LB agar plates containing gentamicin (20 μ g/ml) and incubated for 24 hours before
340 picking colonies for sequence verification.

341 **Plate reader assay for *in vivo* fluorescence**

342 *In vivo* fluorescence was measured using a Biotek (Synergy H1) plate reader. The
343 experiments ran for 24 hours at 30°C using continuous orbital shaking starting from
344 an overnight culture diluted to approximately OD 0.1 into LB medium. OD was
345 measured every 10 minutes at 500 nm and fluorescence was measured at 490/520
346 nm.

347 **Author Information**

348 Current address is 1200 E. California Blvd, MC 138-78, Pasadena, CA 91125. The
349 authors declare no competing interests.

350 **Author Contribution**

351 JTM, EML and RMM conceptualized the project. JTM and EML designed the
352 experiments and analyzed the data. JTM performed TX-TL experiments. EML
353 performed *in vivo* experiments, with the exception of the syringaldehyde experiment
354 which was performed by JTM. EML did the plasmid construction and integration.
355 JTM and EML wrote the manuscript with input from RMM.

356 **Acknowledgements**

357 With thanks to M. Prator for performing the Bradford assays of the lysates, to
358 Z. Jurado for purifying the mNeonGreen fluorescence standard, to Prof. Dianne
359 Newman for the *Pseudomonas* strains and R. Alcalde for the Pa10403-mNeonGreen
360 plasmid and *P. synxantha* strain, to Dr. R. Sidney Cox III for assistance with

361 data visualization, to A. Pandey for assistance with data processing, and to Dr.
362 Dmitri Mavrodi for assistance with the genomic integration protocol for *P. synxan-*
363 *tha*. This research is supported by the Institute for Collaborative Biotechnologies
364 through contract W911NF-19-D-0001, cooperative agreement W911NF-19-2-0026,
365 and grant W911NF-09-0001 from the U.S. Army Research Office, the National Sci-
366 ence Foundation through grant CBET-1903477, and the International Human Fron-
367 tiers Science Program. The content of this paper does not necessarily reflect the
368 position or the policy of the U.S. Government, and no official endorsement should
369 be inferred.

370 References

- 371 [1] D. G. Gibson, L. Young, R.-Y. Chuang, J. C. Venter, C. A. Hutchison III, and
372 H. O. Smith, “Enzymatic assembly of DNA molecules up to several hundred
373 kilobases,” *Nature methods*, vol. 6, no. 5, pp. 343–345, 2009.
- 374 [2] R. Barrangou and J. A. Doudna, “Applications of CRISPR technologies in re-
375 search and beyond,” *Nature biotechnology*, vol. 34, no. 9, pp. 933–941, 2016.
- 376 [3] D.-K. Ro, E. M. Paradise, M. Ouellet, K. J. Fisher, K. L. Newman, J. M.
377 Ndungu, K. A. Ho, R. A. Eachus, T. S. Ham, J. Kirby, *et al.*, “Production of
378 the antimalarial drug precursor artemisinic acid in engineered yeast,” *Nature*,
379 vol. 440, no. 7086, pp. 940–943, 2006.
- 380 [4] J. Zhang, L. G. Hansen, O. Gudich, K. Viehrig, L. M. Lassen, L. Schrübbers,
381 K. B. Adhikari, P. Rubaszka, E. Carrasquer-Alvarez, L. Chen, *et al.*, “A micro-
382 bial supply chain for production of the anti-cancer drug vinblastine,” *Nature*,
383 vol. 609, no. 7926, pp. 341–347, 2022.
- 384 [5] B. Wang, R. I. Kitney, N. Joly, and M. Buck, “Engineering modular and or-
385 thogonal genetic logic gates for robust digital-like synthetic biology,” *Nature*
386 *communications*, vol. 2, no. 1, p. 508, 2011.
- 387 [6] V. Hsiao, Y. Hori, P. W. Rothmund, and R. M. Murray, “A population-based
388 temporal logic gate for timing and recording chemical events,” *Molecular systems*
389 *biology*, vol. 12, no. 5, p. 869, 2016.
- 390 [7] M. Hicks, T. T. Bachmann, and B. Wang, “Synthetic biology enables pro-
391 grammable cell-based biosensors,” *ChemPhysChem*, vol. 21, no. 2, pp. 132–144,
392 2020.

- 393 [8] K. Wetterstrand, “DNA sequencing costs: Data from the NHGRI genome se-
394 quencing program (gsp) available at: www.genome.gov/sequencingcostsdata,”
395 *Accessed August*, 2019.
- 396 [9] R. A. Hughes and A. D. Ellington, “Synthetic DNA synthesis and assembly:
397 putting the synthetic in synthetic biology,” *Cold Spring Harbor Perspectives in*
398 *Biology*, vol. 9, no. 1, p. a023812, 2017.
- 399 [10] E. W. Sayers, M. Cavanaugh, K. Clark, K. D. Pruitt, C. L. Schoch, S. T.
400 Sherry, and I. Karsch-Mizrachi, “Genbank,” *Nucleic Acids Research*, vol. 50,
401 no. D1, p. D161, 2022.
- 402 [11] J. Jumper, R. Evans, A. Pritzel, T. Green, M. Figurnov, O. Ronneberger,
403 K. Tunyasuvunakool, R. Bates, A. Žídek, A. Potapenko, *et al.*, “Highly ac-
404 curate protein structure prediction with alphafold,” *Nature*, vol. 596, no. 7873,
405 pp. 583–589, 2021.
- 406 [12] A. A. Nielsen, B. S. Der, J. Shin, P. Vaidyanathan, V. Paralanov, E. A. Strychal-
407 ski, D. Ross, D. Densmore, and C. A. Voigt, “Genetic circuit design automation,”
408 *Science*, vol. 352, no. 6281, p. aac7341, 2016.
- 409 [13] A. J. Meyer, T. H. Segall-Shapiro, E. Glassey, J. Zhang, and C. A. Voigt, “Es-
410 cherichia coli “marionette” strains with 12 highly optimized small-molecule sen-
411 sors,” *Nature Chemical Biology*, vol. 15, no. 2, pp. 196–204, 2019.
- 412 [14] B. Canton, A. Labno, and D. Endy, “Refinement and standardization of syn-
413 thetic biological parts and devices,” *Nature Biotechnology*, vol. 26, no. 7,
414 pp. 787–793, 2008.
- 415 [15] C. Knief, A. Lipski, and P. F. Dunfield, “Diversity and activity of methan-
416 otrophic bacteria in different upland soils,” *Applied and Environmental Micro-*
417 *biology*, vol. 69, no. 11, pp. 6703–6714, 2003.
- 418 [16] J.-L. Ramos, M. Sol Cuenca, C. Molina-Santiago, A. Segura, E. Duque, M. R.
419 Gómez-García, Z. Udaondo, and A. Roca, “Mechanisms of solvent resistance
420 mediated by interplay of cellular factors in pseudomonas putida,” *FEMS Micro-*
421 *biology Reviews*, vol. 39, no. 4, pp. 555–566, 2015.
- 422 [17] H. E. Knights, B. Jorin, T. L. Haskett, and P. S. Poole, “Deciphering bacterial
423 mechanisms of root colonization,” *Environmental Microbiology Reports*, vol. 13,
424 no. 4, pp. 428–444, 2021.

- 425 [18] T. Bjarnsholt, P. Ø. Jensen, M. J. Fiandaca, J. Pedersen, C. R. Hansen, C. B.
426 Andersen, T. Pressler, M. Givskov, and N. Høiby, “Pseudomonas aeruginosa
427 biofilms in the respiratory tract of cystic fibrosis patients,” *Pediatric Pul-*
428 *monology*, vol. 44, no. 6, pp. 547–558, 2009.
- 429 [19] S. V. Nyholm and M. J. McFall-Ngai, “A lasting symbiosis: how the hawai-
430 ian bobtail squid finds and keeps its bioluminescent bacterial partner,” *Nature*
431 *Reviews Microbiology*, vol. 19, no. 10, pp. 666–679, 2021.
- 432 [20] B. W. Biggs, S. R. Bedore, E. Arvay, S. Huang, H. Subramanian, E. A. McIn-
433 tyre, C. V. Duscent-Maitland, E. L. Neidle, and K. E. J. Tyo, “Development of
434 a genetic toolset for the highly engineerable and metabolically versatile *Acine-*
435 *tobacter baylyi* ADP1,” *Nucleic Acids Research*, vol. 48, no. 9, pp. 5169–5182,
436 2020.
- 437 [21] M. Taketani, J. Zhang, S. Zhang, A. J. Triassi, Y.-J. Huang, L. G. Griffith,
438 and C. A. Voigt, “Genetic circuit design automation for the gut resident species
439 *bacteroides thetaiotaomicron*,” *Nature Biotechnology*, vol. 38, no. 8, pp. 962–
440 969, 2020.
- 441 [22] W. R. Whitaker, E. S. Shepherd, and J. L. Sonnenburg, “Tunable expression
442 tools enable single-cell strain distinction in the gut microbiome,” *Cell*, vol. 169,
443 no. 3, pp. 538–546, 2017.
- 444 [23] L. E. Leiva and A. Katz, “Regulation of leaderless mRNA translation in bacte-
445 ria,” *Microorganisms*, vol. 10, Mar. 2022.
- 446 [24] S. D. Cole, A. E. Miklos, A. C. Chiao, Z. Z. Sun, and M. W. Lux, “Method-
447 ologies for preparation of prokaryotic extracts for cell-free expression systems,”
448 *Synthetic and Systems Biotechnology*, vol. 5, no. 4, pp. 252–267, 2020.
- 449 [25] S. J. Moore, J. T. MacDonald, S. Wienecke, A. Ishwarbhai, A. Tsipa, R. Aw,
450 N. Kylilis, D. J. Bell, D. W. McClymont, K. Jensen, *et al.*, “Rapid acquisition
451 and model-based analysis of cell-free transcription–translation reactions from
452 nonmodel bacteria,” *Proceedings of the National Academy of Sciences*, vol. 115,
453 no. 19, pp. E4340–E4349, 2018.
- 454 [26] S. J. Moore, H.-E. Lai, J. Li, and P. S. Freemont, “Streptomyces cell-free systems
455 for natural product discovery and engineering,” *Natural product reports*, 2023.
- 456 [27] L. S. Thomashow and D. M. Weller, “Role of a phenazine antibiotic from pseu-
457 domonas fluorescens in biological control of gaeumannomyces graminis var. trit-
458 ici,” *Journal of bacteriology*, vol. 170, no. 8, pp. 3499–3508, 1988.

- 459 [28] D. Haas and G. Défago, “Biological control of soil-borne pathogens by fluorescent
460 pseudomonads,” *Nature Reviews Microbiology*, vol. 3, no. 4, pp. 307–319, 2005.
- 461 [29] D. L. McRose and D. K. Newman, “Redox-active antibiotics enhance phosphorus
462 bioavailability,” *Science*, vol. 371, no. 6533, pp. 1033–1037, 2021.
- 463 [30] H. B. Klinke, A. Thomsen, and B. K. Ahring, “Inhibition of ethanol-producing
464 yeast and bacteria by degradation products produced during pre-treatment of
465 biomass,” *Applied Microbiology and Biotechnology*, vol. 66, pp. 10–26, 2004.
- 466 [31] J. Hirose, A. Nagayoshi, N. Yamanaka, Y. Araki, and H. Yokoi, “Isolation and
467 characterization of bacteria capable of metabolizing lignin-derived low molecular
468 weight compounds,” *Biotechnology and bioprocess engineering*, vol. 18, pp. 736–
469 741, 2013.
- 470 [32] T. Kuhnigk and H. König, “Degradation of dimeric lignin model compounds by
471 aerobic bacteria isolated from the hindgut of xylophagous termites,” *Journal of
472 Basic Microbiology*, vol. 37, no. 3, pp. 205–211, 1997.
- 473 [33] I. Mahdi, N. Fahsi, M. Hijri, and M. Sobeh, “Antibiotic resistance in plant
474 growth promoting bacteria: A comprehensive review and future perspectives to
475 mitigate potential gene invasion risks,” *Frontiers in Microbiology*, vol. 13, 2022.
- 476 [34] R. Datta, A. Kelkar, D. Baraniya, A. Molaei, A. Moulick, R. S. Meena, and
477 P. Formanek, “Enzymatic degradation of lignin in soil: a review,” *Sustainability*,
478 vol. 9, no. 7, p. 1163, 2017.
- 479 [35] M. Bilal, S. Guo, H. M. N. Iqbal, H. Hu, W. Wang, and X. Zhang, “Engineer-
480 ing pseudomonas for phenazine biosynthesis, regulation, and biotechnological
481 applications: a review,” *World J. Microbiol. Biotechnol.*, vol. 33, p. 191, Oct.
482 2017.
- 483 [36] D. Haas and G. Défago, “Biological control of soil-borne pathogens by fluorescent
484 pseudomonads,” *Nat. Rev. Microbiol.*, vol. 3, pp. 307–319, Apr. 2005.
- 485 [37] K. Nesemann, S. A. Braus-Stromeyer, A. Thuermer, R. Daniel, D. V. Mavrodi,
486 L. S. Thomashow, D. M. Weller, and G. H. Braus, “Draft genome sequence of the
487 phenazine-producing *Pseudomonas fluorescens* strain 2-79,” *Genome Announc.*,
488 vol. 3, Mar. 2015.
- 489 [38] T. Timms-Wilson, R. Ellis, A. Renwick, D. Rhodes, D. Mavrodi, D. M. Weller,
490 L. S. Thomashow, and M. Bailey, “Chromosomal insertion of phenazine-1-
491 carboxylic acid biosynthetic pathway enhances efficacy of damping-off disease

- 492 control by pseudomonas fluorescens,” *Molecular Plant-Microbe Interactions*,
493 vol. 13, no. 12, pp. 1293–1300, 2000.
- 494 [39] J. P. Meier-Kolthoff and M. Göker, “TYGS is an automated high-throughput
495 platform for state-of-the-art genome-based taxonomy,” *Nature Communications*,
496 vol. 10, no. 1, p. 2182, 2019.
- 497 [40] P. I. Nickel, E. Martínez-García, and V. de Lorenzo, “Biotechnological domesti-
498 cation of pseudomonads using synthetic biology,” *Nat. Rev. Microbiol.*, vol. 12,
499 pp. 368–379, May 2014.
- 500 [41] Z. Z. Sun, C. A. Hayes, J. Shin, F. Caschera, R. M. Murray, and V. Noireaux,
501 “Protocols for implementing an escherichia coli based TX-TL cell-free expression
502 system for synthetic biology,” *J. Vis. Exp.*, p. e50762, Sept. 2013.
- 503 [42] Z. Z. Sun, E. Yeung, C. A. Hayes, V. Noireaux, and R. M. Murray, “Linear
504 DNA for rapid prototyping of synthetic biological circuits in an Escherichia coli
505 based tx-tl cell-free system,” *ACS Synthetic Biology*, vol. 3, no. 6, pp. 387–397,
506 2014.
- 507 [43] M. Lanzer and H. Bujard, “Promoters largely determine the efficiency of repres-
508 sor action,” *Proceedings of the National Academy of Sciences*, vol. 85, no. 23,
509 pp. 8973–8977, 1988.
- 510 [44] J. Meisner and J. B. Goldberg, “The Escherichia coli rhaSR-PrhaBAD inducible
511 promoter system allows tightly controlled gene expression over a wide range
512 in Pseudomonas aeruginosa,” *Applied and environmental microbiology*, vol. 82,
513 no. 22, pp. 6715–6727, 2016.
- 514 [45] S. Zobel, I. Benedetti, L. Eisenbach, V. de Lorenzo, N. Wierckx, and L. M.
515 Blank, “Tn7-based device for calibrated heterologous gene expression in Pseu-
516 domonas putida,” *ACS Synthetic Biology*, vol. 4, no. 12, pp. 1341–1351, 2015.
- 517 [46] K.-H. Choi and H. P. Schweizer, “mini-tn 7 insertion in bacteria with single att
518 tn 7 sites: example Pseudomonas aeruginosa,” *Nature Protocols*, vol. 1, no. 1,
519 pp. 153–161, 2006.
- 520 [47] K.-H. Choi, J. B. Gaynor, K. G. White, C. Lopez, C. M. Bosio, R. R. Karkhoff-
521 Schweizer, and H. P. Schweizer, “A tn 7-based broad-range bacterial cloning and
522 expression system,” *Nature Methods*, vol. 2, no. 6, pp. 443–448, 2005.